SAN FRANCISCO — Ertugliflozin may be protective of renal function in patients with type 2 diabetes, according to study results presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019.

Researchers pooled data from 2 randomized controlled trials to evaluate the effect of ertugliflozin on measures of renal function. Participants with type 2 diabetes were divided into groups who received ertugliflozin 5 mg (n = 652), ertugliflozin 15 mg (n = 640), or glimepiride or placebo (n = 644). Changes in estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) from baseline were analyzed using mixed models with treatment, time, glycated hemoglobin, blood pressure, and other baseline measures as covariates.

At baseline, mean eGFR was 88.2 mL/min/1.73 m2 and geometric mean UACR was 11.6 mg/g. After 6 weeks, patients receiving ertugliflozin 5 or 15 mg showed greater reductions in eGFR compared with patients not receiving ertugliflozin (-2.3 and -2.7 vs -0.7 mL/min/1.73 m2, respectively). However, this trend reversed over time for the ertugliflozin groups while reductions in eGFR were observed in the non-ertugliflozin group.

Continue Reading

After 2 years, change in eGFR was 1.81 and 2.10 mL/min/1.73 m2 for the groups receiving ertugliflozin 5 and 15 mg, respectively, compared with patients receiving placebo or glimepiride.

Related Articles

For change in mean UACR after 2 years, the ertugliflozin 5 and 15 mg groups showed a -29.0% and -32.7% change, respectively, compared with the group not receiving ertugliflozin. Patients with baseline albuminuria (UACR >30 mg/g; n = 415) had greater UACR reductions after receiving ertugliflozin vs the comparators.

The researchers indicated that the results are suggestive of renal function preservation given the association between ertugliflozin and higher eGRF values over time.


Cherney D, Heerspink HL, Frederich R, et al. Two-year effects of ertugliflozin on renal function. Presented at: American Diabetes Association 79th Scientific Sessions; June 7-11, 2019; San Francisco, CA. Poster 1197-P.

This article originally appeared on Endocrinology Advisor